Comparison

ly3200882

Item no. V3756-250mg
Manufacturer InvivoChem LLC
CASRN 1898283-02-7
Amount 250mg
Category
Type Biochemicals
Specific against other
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Available
Description
InvivoChem Cat #:V3756CAS #: 1898283-02-7Purity >=98%

Description: LY3200882 is a next generation, ATP competitive, potent, highly selective small molecule inhibitor of TGF-beta receptor type 1 (TGFbetaRI). It inhibits the serine-threonine kinase domain of TGFbetaRI. LY3200882 inhibits various pro-tumorigenic activities. LY3200882 potently inhibits TGFbeta mediated SMAD phosphorylation in vitro in tumor and immune cells and in vivo in subcutaneous tumors in a dose dependent fashion. In preclinical tumor models, LY3200882 showed potent anti-tumor activity in the orthotopic 4T1-LP model of triple negative breast cancer and this activity correlated with enhanced tumor infiltrating lymphocytes in the tumor microenvironment.

References: AACR; Cancer Res 2017; 77(13 Suppl):Abstract nr 955.

Molecular Weight (MW)
435.53
Formula
C24H29N5O3
CAS No.
1898283-02-7
Storage
-20C for 3 years in powder form
-80C for 2 years in solvent
Solubility (In vitro)
DMSO: 130 mg/mL
Water: N/A
Ethanol: N/A
Chemical Name
2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol
Synonyms
LY 3200882; LY3200882; LY-3200882;

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 250mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close